Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mamta Gupta

Showing results (121-130 of 131) with videos related to

Pageof 14
Sort By:
Blood|September 12, 2012
t(X;14)(p11;q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growthStephen M Ansell, Takashi Akasaka, Ellen McPhail, et al.
Cancer Immunology Research|May 28, 2015
Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell CarcinomaMarcella Callea, Laurence Albiges, Mamta Gupta, et al.
Cancers|August 26, 2022
DWI Metrics Differentiating Benign Intraductal Papillary Mucinous Neoplasms from Invasive Pancreatic Cancer: A Study in GEM ModelsMiguel Romanello Joaquim, Emma E Furth, Yong Fan, et al.
Blood|April 30, 2015
The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphomaThomas E Witzig, Craig Reeder, Jing Jing Han, et al.
American Journal of Hematology|September 18, 2014
Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin lymphomaThomas E Witzig, Matthew J Maurer, Thomas M Habermann, et al.
Blood|November 15, 2011
Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignanciesMamta Gupta, Andrea E Wahner Hendrickson, Seong Seok Yun, et al.
American Journal of Hematology|April 27, 2013
A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphomaThomas E Witzig, Gregory A Wiseman, Matthew J Maurer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2011
Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphomaMatthew J Maurer, Ivana N M Micallef, James R Cerhan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2017
Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian CancerDouglass W Tucker, Christopher R Getchell, Eric T McCarthy, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|May 12, 2018
Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC)Helena M Ditzel, Kyle C Strickland, Emily E Meserve, et al.
Pageof 14

Showing results (121-130 of 131) with videos related to

Sort By:
Pageof 14
Blood|September 12, 2012
t(X;14)(p11;q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growthStephen M Ansell, Takashi Akasaka, Ellen McPhail, et al.
Cancer Immunology Research|May 28, 2015
Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell CarcinomaMarcella Callea, Laurence Albiges, Mamta Gupta, et al.
Cancers|August 26, 2022
DWI Metrics Differentiating Benign Intraductal Papillary Mucinous Neoplasms from Invasive Pancreatic Cancer: A Study in GEM ModelsMiguel Romanello Joaquim, Emma E Furth, Yong Fan, et al.
Blood|April 30, 2015
The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphomaThomas E Witzig, Craig Reeder, Jing Jing Han, et al.
American Journal of Hematology|September 18, 2014
Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin lymphomaThomas E Witzig, Matthew J Maurer, Thomas M Habermann, et al.
Blood|November 15, 2011
Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignanciesMamta Gupta, Andrea E Wahner Hendrickson, Seong Seok Yun, et al.
American Journal of Hematology|April 27, 2013
A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphomaThomas E Witzig, Gregory A Wiseman, Matthew J Maurer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2011
Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphomaMatthew J Maurer, Ivana N M Micallef, James R Cerhan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2017
Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian CancerDouglass W Tucker, Christopher R Getchell, Eric T McCarthy, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|May 12, 2018
Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC)Helena M Ditzel, Kyle C Strickland, Emily E Meserve, et al.
Pageof 14